Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma
Sponsor: NanOlogy, LLC
A PHASE1/PHASE2 clinical study on Bladder Cancer and Cancer of the Bladder, this trial is completed. The trial is conducted by NanOlogy, LLC and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Sep 2023 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Oct 2019 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NanOlogy, LLC
- US Biotest, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .